Research programme: human papillomavirus vaccine - Biotech Australia/University of Queensland

Drug Profile

Research programme: human papillomavirus vaccine - Biotech Australia/University of Queensland

Latest Information Update: 30 May 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biotech Australia; The University of Queensland
  • Class
  • Mechanism of Action Helper-inducer T-lymphocyte modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cervical cancer

Most Recent Events

  • 18 Nov 2002 No development reported - Preclinical for Cervical cancer in Australia (Parenteral)
  • 18 May 1999 A study has been added to the adverse events section and the Viral Infections immunogenicity section
  • 14 Sep 1998 Phase-I clinical trials for Cervical cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top